Home

About Us

Strategy

News

Careers Contact Us

CN | EN

About Us

Founded in December 2017，We are a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutic candidates to treat cancer and Nephropathy.

Strategy

            Joint R&D for potential BIC pipeline
          
            2017-12-28
          
            Building a leading edge in the clinical trial system
          
            Enhancing in-house R&D capabilities and Transforming to Global Innovation
          
            Integrate resources to strengthen commercialization capabilities

News

05 2024.11

BioCity presents late-breaking clinical trial results with SC0062 for IgA Nephropathy at ASN Kidney Week 2024 as published in the Journal of the American Society of Nephrology

29 2024.09

Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024

promising interim phase I clinical data of BC3195

29 2024.09

Breakthrough Therapy Designation (BTD) for BioCity's SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria

BTD granted by NMPA

12 2024.09

BioCity to Present Preliminary Phase I Results of BC3195 (CDH3 ADC) at 2024 ESMO Congress

a further update on the Phase I clinical progress of BC3195

Career

We have always been adhering to the mission of "Better Medicine for Better Life", and dedicate to developing "BIC/FIC" drugs with unmet needs.
We invite like-minded you to join us to create a healing tomorrow together.

Join Us